CSPC Pharma wins China clinical trial clearance for SYH9102 goserelin injection

PUBT · 1d ago
CSPC Pharma wins China clinical trial clearance for SYH9102 goserelin injection
  • CSPC Pharmaceutical Group received China NMPA clearance to start clinical trials of its goserelin sustained-release injection, SYH9102.
  • Program targets solid tumor patients; the drug is a once-monthly, ready-to-use formulation designed to simplify administration versus existing goserelin products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12326260), on September 09, 2026, and is solely responsible for the information contained therein.